Pliant Therapeutics, a clinical-stage biotechnology company founded by UCSF researchers Bill Degrado and Dean Sheppard, with a focus on discovering and developing novel therapeutics for the treatment of fibrosis, today announced positive interim results from a Phase 2a positron emission tomography (PET) imaging-based clinical trial of PLN-74809, an oral small molecule dual selective inhibitor of αvβ6/αvβ1, in patients with idiopathic pulmonary fibrosis (IPF).
